New cocktail of three drugs shows promise for Tough-to-Treat uterine cancer

NCT ID NCT02755844

Completed Disease control Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a combination of three drugs—olaparib, metformin, and cyclophosphamide—in 35 women with recurrent advanced endometrial cancer that had already been treated with chemotherapy. The goal was to find a safe dose and see if the combination could stop the cancer from growing. If successful, this could provide a new treatment option for patients with few alternatives.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: olaparib, metformin, and cyclophosphamide
What this could lead to: If this combination works, it could offer a new treatment option for women with recurrent endometrial cancer who have run out of effective therapies.
What could go wrong: This is an early-phase trial with only 35 participants, so results may not apply to all patients. The drug combination may cause side effects or fail to control the cancer long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial carcinoma endometrium neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT ENDOMETRIAL CANCER

Contacts and locations

Locations

Centre Hospitalier Lyon Sud

Pierre-Bénite, 69495, France
Comité Gynécologique, Institut Gustave Roussy

Villejuif, 94800, France
Département d'Oncologie Médicale, Centre Antoine Lacassagne

Nice, 06189, France
Département de Cancérologie Cervico-Faciale et Thoracique, Centre Oscar Lambret

Lille, 59000, France
Service d'Oncologie Médicale, Centre François Baclesse

Caen, 14076, France
Service d'Oncologie Médicale, Institut Curie

Paris, 75248, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.